Cell News and Research

RSS

AVMA warns against further restrictions on cephalosporin usage in food animals that are not backed by science

The American Veterinary Medical Association (AVMA) announced today that the FDA's order prohibiting certain uses of cephalosporins in food animals appears consistent with the current AVMA position on the limited prohibition on extra-label drug use, but warned against further restrictions not backed by science.

7 Jan 2012

AnaptysBio enters new strategic alliances for antibody discovery

AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced the initiation of new strategic alliances with two partners: Novartis and an undisclosed second pharmaceutical company.

7 Jan 2012

Study provides hope for stimulating remyelination in MS patients

Scientists at Joslin Diabetes Center, Harvard University, and the University of Cambridge have found that the age-related impairment of the body's ability to replace protective myelin sheaths, which normally surround nerve fibers and allow them to send signals properly, may be reversible, offering new hope that therapeutic strategies aimed at restoring efficient regeneration can be effective in the central nervous system throughout life.

7 Jan 2012

Age-associated decline of remyelination process may be reversible

New research highlights the possibility of reversing ageing in the central nervous system for multiple sclerosis (MS) patients. The study is published today, 06 January, in the journal Cell Stem Cell.

7 Jan 2012

Poor nutrition in the womb can increase risk of type 2 diabetes in later life

Researchers funded by the Biotechnology and Biological Sciences Research Council have shown one way in which poor nutrition in the womb can put a person at greater risk of developing type 2 diabetes and other age-related diseases in later life.

7 Jan 2012

The Tech Group, Pepex partner to develop Trio systems and sensor modules

Pepex Biomedical, Inc., a privately held company that has developed an all new proprietary sensor technology known as "CCM", announced today it has reached an agreement with The Tech Group , a division of West Pharmaceuticals Services, Inc., to be the premier manufacturer of the Trio systems and sensor modules.

7 Jan 2012

Researchers crack structure and function of malarial protein

A biology lab at Washington University has just cracked the structure and function of a protein that plays a key role in the life of a parasite that killed 655,000 people in 2010.

7 Jan 2012

SPIE to honor CCNY professor with Britton Chance Biomedical Optics Award

A scientific innovator from The City College of New York (CCNY) whose research unites the divergent fields of medicine, biology and high-speed laser physics will be honored this month for his pioneering work in biomedical optics by SPIE, the international society for optics and photonics.

7 Jan 2012

PCI Biotech focuses on localised cancer therapy with minimum side effects

Side effects are currently the biggest problem with any cancer treatment. A Norwegian biotech company is drawing closer to the goal of creating a treatment which kills only cancer cells, leaving other cells unaffected.

7 Jan 2012

VisionGate achieves full automation of Cell-CT system

VisionGate, Inc., a company developing a revolutionary non-invasive test for the early detection of lung cancer and other applications, today reported that it has achieved full automation of its Cell-CT system, a proprietary imaging platform that generates high-resolution 3D biosignatures from intact cells.

7 Jan 2012

Studies identify genes and small molecules against protein conformational diseases

Two related studies from Northwestern University offer new strategies for tackling the challenges of preventing and treating diseases of protein folding, such as Alzheimer's, Parkinson's and Huntington's diseases, amyotrophic lateral sclerosis (ALS), cancer, cystic fibrosis and type 2 diabetes.

7 Jan 2012

Alnylam files CTA with the U.K. MHRA to initiate ALN-TTR02 Phase I trial in ATTR

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-TTR02, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis.

7 Jan 2012

GSN completes $20M financing round

Gene Security Network Inc. (GSN) today announced the completion of a $20 million financing round, as well as the change of the company's name to Natera, Inc. The financing round was led by Lightspeed Venture Partners, which is joined in the current round by Claremont Creek Ventures and Sequoia Capital.

7 Jan 2012

GSK obtains exclusive license to ChemoCentryx's CCX354 CCR1 inhibitor for RA

ChemoCentryx, Inc., today announced that GlaxoSmithKline (GSK) has exercised its option to obtain an exclusive license for further development and worldwide commercialization of the investigational medicine CCX354, a potent and selective inhibitor of CCR1, a chemokine receptor that drives the recruitment of inflammatory cells into the joints of patients with rheumatoid arthritis (RA).

6 Jan 2012

TrovaGene enters definitive agreement to acquire MultiGEN

TrovaGene, Inc., a developer of trans-renal molecular diagnostics, today announced that it has entered into a definitive agreement to acquire MultiGEN Diagnostics, Inc.'s clinical laboratory assets in exchange for the issuance of 750,000 shares of common stock of TrovaGene, with an additional earn-out of up to $3.7 million in cash and common stock, subject to the achievement of specific sales and earnings targets.

6 Jan 2012